Multiple Myeloma (MM) is generally incurable and patients will eventually develop relapsed/refractory disease. Early relapse is associated with poor clinical outcomes and overall survival.
As a co-investigator on this project and leader of the GE3LS research activities, Dr. Regier leads the health economics activities of the LSARP project.
The Silent Genomes project aims to elucidate and address the health inequities faced by Canadian Indigenous populations when accessing genomic technologies for the diagnosis of genetic diseases.
Dr. Regier’s GeneSolve study, recently funded by Genome British Columbia, examines the value of genomic sequencing for diagnosing childhood rare diseases.
BC Cancer’s Personalized OncoGenomics (POG) Program is a world-leading initiative applying whole-genome and transcriptome analysis (WGTA) to inform real-time treatment decisions for patients with advanced, hard-to-treat cancers. Dr.
Dr. Regier’s CIHR-funded Catalyst project applies a mixed methods approach to enhancing shared decision-making in context to the return of genetic test results for hereditary cancer syndromes.
BC Cancer Foundation is the fundraising partner of BC Cancer, which includes BC Cancer Research. Together with our donors, we are changing cancer outcomes for British Columbians by funding innovative research and personalized treatment and care.